Safety, Blood Levels and Effects of GW642444

Phase 1

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive
• Interventions: Drug: GW642444M for 14 days

• Registration Number: NCT00469040
• Lead Sponsor: GlaxoSmithKline

Brief Summary

GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD). People with asthma and COPD suffer from breathlessness because the small tubes (bronchioles) that carry air in and out of the lungs become narrow. We hope that the study medicine will work by relaxing the muscles in the airways and help to keep the airways open, and make breathing easier. The study medicine might improve on available treatments by having fewer side-effects, and by working faster and for longer, so that patients could take it once daily, instead of twice daily.

When a medicine is made into a form ready to be given to patients, inactive ingredients are often added. Inactive ingredients might be used to help a medicine work better, to make it easier to produce the medicine, or to make it easier to get an accurate dose of medicine. In this study, the study medicine contains the inactive ingredient magnesium stearate.

We need to check that the study medicine doesn't cause problems when inhaled along with magnesium stearate. So, we're doing this study in healthy people to find out the answers to these questions.

1)Do repeated once-daily doses of the study medicine cause any important side effects when inhaled, along with magnesium stearate, as a fine powder? 2)How much of the study medicine gets into the bloodstream and how long does the body take to get rid of it?

Detailed Description

Not available

Study Timeline

• Study Start: 2007-02-28
• Primary Completion: 2007-04-16
• Study Completion: 2007-04-16
• Study First Submitted: 2007-05-03
• Study First Submitted QC: 2007-05-03
• Study First Posted: 2007-05-04
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-02
• Last Update Posted: 2017-08-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GW642444M 50mcg	GW642444M for 14 days	Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
GW642444M 25mcg	GW642444M for 14 days	In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
GW642444M 100mcg	GW642444M for 14 days	In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
GW642444M 200mcg	GW642444M for 14 days	Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
GW642444M 400mcg	GW642444M for 14 days	Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.

Primary Outcome Measures

Name	Time	Method
General safety and tolerability as measured by ECG, blood pressure, pulse rate and blood and urine tests. Repeated measures on Day 1, 7 and 14	Repeated measures on Day 1, 7 and 14

Secondary Outcome Measures

Name	Time	Method
Effects of the medicine on the body as measured by potassium and glucose levels in the blood. Monitoring of the study medicine in the body by analysis of blood samples. Repeated measures on Day 1, 7 and 14	Repeated measures on Day 1, 7 and 14

Trial Locations

Locations (1)

GSK Investigational Site; 🇬🇧 London, United Kingdom